Biomarkers: The Now and The Future
From diagnostic tools to clinical trial enrichment and surrogate endpoint markers, biomarkers are important tools that have the potential to reduce the length, cost, and uncertainty of drug development. A...
Orphan Drugs & Diseases
In the 1960s, the United States congress passed the “Drug Efficacy Amendment”, which introduced for the first time a requirement for pharmaceutical companies to disclose side effects and dangers of...
Recent Comments